FG-3163

FG-3163 is an investigational **anti-CCR8 antibody** being developed by FibroGen for oncology indications, specifically to target immunosuppressive cells within the tumor microenvironment. It is designed to **selectively deplete suppressive T regulatory cells (Tregs)** in tumors, with the goal of activating immune responses against tumor cells and inducing tumor cell killing, all while sparing peripheral T regulatory cells, thereby maintaining normal immune homeostasis. This selective immunomodulation may offer therapeutic benefits across a range of solid tumors. As of late 2023, FG-3163 had not yet entered clinical trials but was anticipated to begin first-in-human studies following IND filing in Q4 2023[1][3][4][5].